FATE Q4 2022 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M+159.9% YoY

Gross Profit

-$43M-96.6% margin

Operating Income

-$64M-145.2% margin

Net Income

-$56M-127.1% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

+196.1%

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$82M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$706M

Total Liabilities

$222M

Stockholders' Equity

$484M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$17M	+159.9%
Gross Profit	-$43M	-$52M	+18.3%
Operating Income	-$64M	-$69M	+7.2%
Net Income	-$56M	-$69M	+17.9%

Revenue Segments

Upfront Fee And Equity Premium

$6M100%